DBV Tech grabs $25M C round for allergy drug trials

A pair of new investors--InnoBioFund and Lundbeckfond Ventures--has taken the lead on a $25.5 million Series C round for France's DBV Technologies, And the biotech plans to use that money to fuel its work on new therapies for severe food allergies.

According to Genetic Engineering & Biotechnology News the French company gained FDA clearance on clinical trial work for its peanut allergy therapy with Phase Ib studies now underway. The NIH is supporting Phase II work, which is scheduled to get started at the middle of this year. Shire and Alto Invest joined the round with existing investors Sofinnova Partners and Alk Abello.

- here's the story from Genetic Engineering & Biotechnology News

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.